Accordingly, OX40 appears to be expressed at higher levels in TILs or tumour-draining lymph nodes when compared to PBMC-derived immune cells in melanoma, ductal mamma carcinoma, and head and neck cancer (108–112). Here, TNFRSF4 is linked to neoplasm.